The GLP-1 Challenge

May 16, 2025

Tackle the Toughest GLP-1 Side Effects with Clinically Studied Solutions
Going to Probiota Americas? Don’t miss your chance to meet our probiotic and enzyme experts!

The GLP-1 Challenge

GLP-1 medications are transforming weight management—but at a cost to consumers. Medications such as Ozempic and Wegovy are surging in popularity, but their rapid adoption has brought new, urgent problems to the forefront.

With 12% of U.S. consumers already using these drugs and 32% actively aware of their potential, the market is booming—but so are the side effects.1

Up to 70% of GLP-1 users experience gastrointestinal (GI) distress, including nausea, vomiting and diarrhea2
86% struggle to meet protein needs, increasing the risk of muscle loss and metabolic slowdown3

The result? Non-adherence, dropouts and a growing need for effective companion products that support the entire GLP-1 journey—from first dose to long-term success.

Companion Products Are No Longer Optional

For brands and formulators, the message is clear: companion products aren’t just a trend, they’re a necessity.

GI discomfort and muscle retention are two areas where formulators must provide options. Meeting these needs isn’t just about consumer satisfaction; it’s about product differentiation and long-term loyalty.

To help you meet this demand, we offer science-backed ingredients designed to target the two most significant consumer pain points.

Our Science-Driven Solutions – SEBiotic® & DigeSEB Sport™

Support GI Health with SEBiotic®

SEBiotic® (Bacillus coagulans LBSC) is a powerful spore-forming, soil-based (SBO) probiotic backed by 14 published studies.

Supports reduction in nausea, vomiting and diarrhea
Promotes gut microbiome balance
Shelf-stable and resistant to extreme temperatures and pH levels
Recognized as safe and effective with FDA GRAS No Objections Letter and Health Canada NPN (Natural Product Number) and claims

Whether you’re formulating a supplement, functional food or beverage, SEBiotic® can help ensure repeat purchases by supporting gut health and promoting less GI discomfort for consumers on GLP-1s.

Promote Protein Digestion for Muscle Building with DigeSEB Sport™

As appetite drops for consumers taking GLP-1 agonists, so does protein intake, which can lead to muscle loss. That’s where clinically studied DigeSEB Sport™ steps in.

Backed by 2 clinical studies
Supports optimal protein digestion
Supports amino acid absorption for muscle synthesis
Promotes postbiotic production to support a healthy response to inflammation and muscle building

Perfect for high-protein applications like powders, bars and ready-to-drink shakes, DigeSEB Sport™ helps consumers make the most of every gram of protein.

Seize the Strategic Advantage

GLP-1 companion products present a high-growth opportunity for formulators ready to solve real-world problems. By incorporating SEBiotic® and DigeSEB Sport™ into your products, you can

Stand out with clinically supported, research-driven ingredients
Address both GI discomfort and muscle preservation—top concerns for GLP-1 users
Create products that consumers trust and keep purchasing

This is your time to innovate in the GLP-1 space. Let’s build better products—together.

Attend Our Round Table | June 10

Key Regulatory Insights to Enhance Your Global Strategy

Navigating global regulations isn’t easy. With different standards across the U.S., Canada, the EU, and beyond, understanding where and how to make claims is crucial. Join Ankit Rathi, Director of Quality & Regulatory Affairs, at our Probiota Americas Round Table and learn from a team that’s worked with regulatory bodies around the world for decades.

Meet Us at Probiota Americas

Connect with our team of probiotic and enzyme experts at Probiota Americas, June 9-11, to discuss how to make your products even better.

Sources

1. Alex Montero, G. S. (2024, May 10). KFF Health Tracking Poll May 2024: The public’s use and views of GLP-1 Drugs. KFF. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

2. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, García-de-Lucas MD, Núñez J, Obaya JC, Soler MJ, Górriz JL, Rubio-Herrera MÁ. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022 Dec 24;12(1):145. doi: 10.3390/jcm12010145. PMID: 36614945; PMCID: PMC9821052.

Menu

The GLP-1 Challenge